Regulation of OCT2 transcriptional repression by histone acetylation in renal cell carcinoma

References

• Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010;58(3):398–406.
   PubMed Web of Science ®Google Scholar
• Baldewijns MM, van Vlodrop IJ, Schouten LJ, et al. Genetics and epigenetics of renal cell cancer. Biochim Biophys Acta. 2008;1785(2):133–155.
   PubMed Web of Science ®Google Scholar
• Gorboulev V, Ulzheimer JC, Akhoundova A, et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997;16(7):871–881.
   PubMed Web of Science ®Google Scholar
• Motohashi H, Sakurai Y, Saito H, et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol. 2002;13(4):866–874.
   PubMed Web of Science ®Google Scholar
• Prasad B, Johnson K, Billington S, et al. Abundance of drug transporters in the human kidney cortex as quantified by quantitative targeted proteomics. Drug Metab Dispos. 2016;44(12):1920–1924.
   PubMed Web of Science ®Google Scholar
• Koepsell H, Gorboulev V, Arndt P. Molecular pharmacology of organic cation transporters in kidney. J Membr Biol. 1999;167(2):103–117.
   PubMed Web of Science ®Google Scholar
• Pritchard JB, Miller DS. Renal secretion of organic anions and cations. Kidney Int. 1996;49(6):1649–1654.
   PubMed Web of Science ®Google Scholar
• Budiman T, Bamberg E, Koepsell H, et al. Mechanism of electrogenic cation transport by the cloned organic cation transporter 2 from rat. J Biol Chem. 2000;275(38):29413–29420.
   PubMed Web of Science ®Google Scholar
• Burger H, Zoumaro-Djayoon A, Boersma AW, et al. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol. 2010;159(4):898–908.
   PubMed Web of Science ®Google Scholar
• Zhang S, Lovejoy KS, Shima JE, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006;66(17):8847–8857.
   PubMed Web of Science ®Google Scholar
• Yao Z, Guo H, Yuan Y, et al. Retrospective analysis of docetaxel, oxaliplatin plus fluorouracil compared with epirubicin, cisplatin and fluorouracil as first-line therapy for advanced gastric cancer. J Chemother. 2014;26(2):117–121.
   PubMed Web of Science ®Google Scholar
• Yokoo S, Masuda S, Yonezawa A, et al. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab Dispos. 2008;36(11):2299–2306.
   PubMed Web of Science ®Google Scholar
• McMurry MT, Krangel MS. Pillars article: a role for histone acetylation in the developmental regulation of V(D)J recombination. Science. 2000;287:495–498.
   PubMed Web of Science ®Google Scholar
• Wurtele H, Li Q, Zhou H, et al. Histone acetylation and chromatin assembly. Med Sci. 2009;25(2):121–122.
   Google Scholar
• Dedes KJ, Dedes I, Imesch P, et al. Acquired vorinostat resistance shows partial cross-resistance to ‘second-generation’ HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities. Anticancer Drugs. 2009;20(5):321–333.
   PubMed Web of Science ®Google Scholar
• Jin Q, Yu LR, Wang L, et al. Distinct roles of GCN5/PCAF-mediated H3K9ac and CBP/p300-mediated H3K18/27ac in nuclear receptor transactivation. Embo J. 2011;30(2):249–262.
   PubMed Web of Science ®Google Scholar
• Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016;6(10):a026831.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zheng X, Yu Q, et al. Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin. Sci Transl Med. 2016;8(348):348r–97r.
   Web of Science ®Google Scholar
• Stewart DJ, Issa JP, Kurzrock R, et al. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res. 2009;15(11):3881–3888.
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–924.
   PubMed Web of Science ®Google Scholar
• Fang F, Balch C, Schilder J, et al. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer. 2010;116(17):4043–4053.
   PubMed Web of Science ®Google Scholar
• Chiappinelli KB, Zahnow CA, Ahuja N, et al. Combining epigenetic and immunotherapy to combat cancer. Cancer Res. 2016;76(7):1683–1689.
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–446.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. New Engl J Med. 1996;335(12):865.
   PubMed Web of Science ®Google Scholar
• Cohen HT, McGovern FJ. Renal-cell carcinoma. New Engl J Med. 2005;353(23):2477.
   PubMed Web of Science ®Google Scholar
• Fletcher JI, Haber M, Henderson MJ, et al. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer. 2010;10(2):147–156.
   PubMed Web of Science ®Google Scholar
• Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4(4):307–320.
   PubMed Web of Science ®Google Scholar
• Dai B, Kim O, Xie Y, et al. Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. Cancer Res. 2006;66(16):8058–8064.
   PubMed Web of Science ®Google Scholar
• Sengupta D, Kannan A, Kern M, et al. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma. Epigenetics. 2015;10(6):460–466.
   PubMed Web of Science ®Google Scholar
• Lehrmann H, Pritchard LL, Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res. 2002;86:41–65.
   PubMed Web of Science ®Google Scholar
• Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009;280(2):168–176.
   PubMed Web of Science ®Google Scholar
• Osada H, Tatematsu Y, Saito H, et al. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer. 2004;112(1):26–32.
   PubMed Web of Science ®Google Scholar
• Ouaissi M, Sielezneff I, Silvestre R, et al. High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann Surg Oncol. 2008;15(8):2318–2328.
   PubMed Web of Science ®Google Scholar
• Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol. 2012;6(6):579–589.
   PubMed Web of Science ®Google Scholar
• McMahon SB, Van Buskirk HA, Dugan KA, et al. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell. 1998;94(3):363–374.
   PubMed Web of Science ®Google Scholar
• Frank SR, Parisi T, Taubert S, et al. MYC recruits the TIP60 histone acetyltransferase complex to chromatin. EMBO Rep. 2003;4(6):575–580.
   PubMed Web of Science ®Google Scholar
• Su R, Gong JN, Chen MT, et al. c-Myc suppresses miR-451 YWTAZ/AKT axis via recruiting HDAC3 in acute myeloid leukemia. Oncotarget. 2016;7(47):77430–77443.
   PubMedGoogle Scholar
• Rountree MR, Bachman KE, Herman JG, et al. DNA methylation, chromatin inheritance, and cancer. Oncogene. 2001;20(24):3156–3165.
   PubMed Web of Science ®Google Scholar
• Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007;7(8):573–584.
   PubMed Web of Science ®Google Scholar
• Efferth T. Resistance to targeted ABC transporters in cancer. Springer International Publishing Switzerland; 2015.
   Google Scholar
• Yu Q, Liu Y, Zheng X, et al. Histone H3 lysine 4 trimethylation, lysine 27 trimethylation, and lysine 27 acetylation contribute to the transcriptional repression of solute carrier family 47 member 2 in renal cell carcinoma. Drug Metab Dispos. 2017;45(1):109–117.
   PubMed Web of Science ®Google Scholar
• Chen MY, Liao WS, Lu Z, et al. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer. 2011;117(19):4424–4438.
   PubMed Web of Science ®Google Scholar
• Dong Y, Desmond JC, Ong JM, et al. Suberoylanilide hydroxamic acid (SAHA) crosses the blood-brain barrier and inhibits growth of human multiforme glioblastomas in the brains of immunodeficient mice. Cancer Res. 2005;65:S771.
   Google Scholar
• Paddison PJ, Cleary M, Silva JM, et al. Cloning of short hairpin RNAs for gene knockdown in mammalian cells. Nat Methods. 2004;1(2):163–167.
   PubMed Web of Science ®Google Scholar
• Richon VM, Webb Y, Merger R, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA. 1996;93(12):5705–5708.
   PubMed Web of Science ®Google Scholar
• Foltman M, Sanchez-Diaz A. Studying protein-protein interactions in budding yeast using co-immunoprecipitation. Methods Mol Biol. 2016;1369:239–256.
   PubMedGoogle Scholar
• Plumb JA. Cell sensitivity assays: the MTT assay. Methods Mol Med. 1999;28:25–30.
   PubMedGoogle Scholar